Table 2.
Changes in cardiometabolic parameters after 6 months of oral semaglutide treatment.
| Clinical Parameters | n | Baseline | After 6 Months | p Value |
|---|---|---|---|---|
| AST (IU/L) | 88 | 22 (18–30.5) | 23 (19.5–28) | 0.065 |
| ALT (IU/L) | 88 | 24 (17.8–38.3) | 23 (20–32) | 0.008 |
| eGFR (mL/min/1.73 m2) | 88 | 74.5 (3.2) | 72.6 (3.3) | 0.055 |
| TC (mg/dL) | 72 | 177 (4.5) | 172 (4.2) | 0.009 |
| HDL-C (mg/dL) | 86 | 49.5 (40.3–56) | 49 (41–57.8) | 0.462 |
| TG (mg/dL) | 87 | 146 (110–202) | 144 (114–181) | 0.028 |
| Non-HDL-C (mg/dL) | 71 | 120 (98–158) | 115 (98–149) | 0.002 |
Data are presented as means (±standard error of the mean, SEM) or median with interquartile range (IQR). p values are calculated by the Wilcoxon signed-rank sum test (vs. baseline parameters). AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.